Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Researchers uncover nuclear organization mechanism linked to Friedreich’s ataxia May 12, 2026 New insights into how smoking influences certain metabolites to increase type 2 diabetes risk October 3, 2023 Diabetes rates surge 18.6% in the U.S., highlighting racial and economic disparities August 25, 2024
New insights into how smoking influences certain metabolites to increase type 2 diabetes risk October 3, 2023